Resolving inflammatory organ disease through macrophage cell therapy

Inflammatory organ disease affects millions of patients worldwide. We aim to treat these patients, for example by helping patients with liver cirrhosis avoiding the need for a transplantation.

The Science +

Harnessing the healing power of the macrophage

Resolution Therapeutics is developing macrophage cell therapies to treat diseases characterised by life-threatening inflammatory organ damage. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution will discover, develop, manufacture and take to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes.

Latest News

12/04/2021

Resolution Therapeutics Appoints Lisa Bright to its Board of Directors

London, 12 April 2021 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases characterised by life-threatening inflammatory organ damage, today announced the appointment of Lisa Bright as a Non-Executive Director of the Company.

READ MORE +
26/01/2021

Resolution: Fighting fibrosis with macrophages

Macrophages are emerging as one of the hottest tools in the fight against cancer, but Resolution is targeting a new application for the cells: attacking fibrosis.

READ MORE +
02/12/2020

Resolution Therapeutics Announces a £26.6m Series A Financing from Syncona Ltd

Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases characterised by life-threatening inflammatory organ damage, today announced completion of a £26.6m Series A financing from Syncona Ltd (“Syncona”).

READ MORE +

Chairman's Statement

Resolution is at the forefront of a new kind of cell therapy. We’re treating inflammatory organ disease with macrophages, the cells that the body uses to resolve injury and heal wounds. Our work builds on a huge body of science understanding the role of macrophages as orchestrators of the wound healing process; coupled with our world-leading founders, a top-quality scientific staff and proprietary insight into macrophage biology and manufacturing, we are poised to improve the lives of countless patients worldwide.

Edward Hodgkin Chairman & CEO